Targets › UBE3A
4 programs from 4 companies in 8 trials: 5 Phase 3, 2 Phase 1, 1 Phase 2; Other; next expected readout Aug 2027.
E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates. Several substrates have been identified including the BMAL1, ARC, LAMTOR1, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B. Additionally, may function as a cellular quality…. (UniProt, Q05086)
Open in Phaseline: the race on UBE3A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals | obudanersen (ION582) antisense oligonucleotide targeting paternal UBE3A mRNA to restore maternal UBE3A expressi | UBE3A | Phase 3 | Angelman Syndrome | Aug 2027 |
| OHB Pediatrics | rugonersen UBE3A antisense oligonucleotide | UBE3A | Phase 3 | Angelman Syndrome | Mar 2029 |
| Ultragenyx Pharmaceutical | GTX-102 (apazunersen) Antisense oligonucleotide targeting UBE3A | UBE3A | Phase 3 | Angelman Syndrome | – |
| MavriX Bio | MVX-220 AAVhu68 viral vector delivering UBE3A gene | UBE3A | Phase 1 | Angelman Syndrome | Mar 2028 |
Angelman Syndrome (8)
other (4)
MavriX Bio (1) Ionis Pharmaceuticals (1) OHB Pediatrics (1) Ultragenyx Pharmaceutical (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.